Fulcrum Therapeutics (FULC) Gains from Sales and Divestitures (2019 - 2025)
Historic Gains from Sales and Divestitures for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $19505.0.
- Fulcrum Therapeutics' Gains from Sales and Divestitures fell 1263.55% to $19505.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $19505.0, marking a year-over-year decrease of 1263.55%. This contributed to the annual value of $22326.0 for FY2024, which is 2304.89% up from last year.
- As of Q3 2025, Fulcrum Therapeutics' Gains from Sales and Divestitures stood at $19505.0, which was down 1263.55% from $19505.0 recorded in Q2 2025.
- Over the past 5 years, Fulcrum Therapeutics' Gains from Sales and Divestitures peaked at $69833.0 during Q4 2021, and registered a low of $5496.0 during Q1 2023.
- In the last 5 years, Fulcrum Therapeutics' Gains from Sales and Divestitures had a median value of $18144.0 in 2023 and averaged $22790.7.
- As far as peak fluctuations go, Fulcrum Therapeutics' Gains from Sales and Divestitures tumbled by 8543.1% in 2022, and later skyrocketed by 11015.28% in 2024.
- Quarter analysis of 5 years shows Fulcrum Therapeutics' Gains from Sales and Divestitures stood at $69833.0 in 2021, then tumbled by 85.43% to $10174.0 in 2022, then skyrocketed by 78.34% to $18144.0 in 2023, then rose by 23.05% to $22326.0 in 2024, then dropped by 12.64% to $19505.0 in 2025.
- Its Gains from Sales and Divestitures was $19505.0 in Q3 2025, compared to $19505.0 in Q2 2025 and $11003.0 in Q1 2025.